Objective: The present study evaluated real-world pediatric glycemia during use of MiniMed™ 780G recommended settings (100 mg/dL* glucose target [GT] and 2hrs active insulin time [AIT]).
Methods: Overall mean TIR, after AHCL initiation, in the pediatric pivotal trial (ages 7-17 years) was 70.3% (N=160).1 For participants using recommended settings >95% of the time, mean TIR was 73.4% (N=19). In this abstract, we present real-world glycemic outcomes in children (≤15 years) from multiple continents using a range of GT and AIT settings, versus the recommended GT and AIT settings. Assented real-world users with ≥10 days of sensor glucose (SG) data from EMEA (N=3,211 in Europe, the Middle East, and Africa) and Latin America (N=332) uploaded system data between Aug 2020-Sep 2022. Outcomes included the mean of SG, glucose management indicator and percentage of time spent below, within and above target (70-180 mg/dL) range.
Results: Real-world outcomes from children in EMEA and Latin America using overall AHCL settings met consensus goals (Figure)2 and TIR increased further when recommended settings were used.
Conclusion: Findings in a population of children from around the world with T1D who used MiniMed™ 780G AHCL at recommended settings (versus a range of settings) had the highest time in range, without compromising time below range.
J.Mcvean: Employee; Medtronic. A.Arrieta: Employee; Medtronic. T.L.Cordero: Employee; Medtronic. M.Castro: Employee; Medtronic. J.Castañeda: Employee; Medtronic. O.Cohen: Employee; Medtronic.
